Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

#Agios is planning to file its #sicklecelldisease (SCD) candidate #mitapivat with the #FDA under the #acceleratedpathway, based on feedback from the US regulator at a recent meeting.